$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000140191420000042 Filed on March 27, 2020

Income Statement

Concept	2020 Q1	2018 Q4	2018
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.870M	$1.300M	$5.280M
YoY Change	34.53%	32.65%	95.56%
% of Gross Profit
Research & Development	$2.380M	$1.660M	$6.414M
YoY Change	40.53%	147.76%	551.33%
% of Gross Profit
Depreciation & Amortization	$11.95K	$0.00	$2.440K
YoY Change	939.04%
% of Gross Profit
Operating Expenses	$4.254M	$2.960M	$16.88M
YoY Change	37.98%	79.39%	51.0%
Operating Profit	-$4.254M		-$16.88M
YoY Change	37.98%		51.0%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.821K	$40.00K	$143.5K
YoY Change	-94.17%		-144.48%
Pretax Income	-$4.250M	-$2.920M	-$16.71M
YoY Change	39.34%	-68.02%	45.24%
Income Tax			$3.200K
% Of Pretax Income
Net Earnings	-$4.252M	-$2.920M	-$16.74M
YoY Change	39.33%	-68.02%	45.52%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$178.6K	-$255.5K	-$1.560M
COMMON SHARES
Basic Shares Outstanding	24.69M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2018 Q4	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.050M	$6.810M	$6.810M
YoY Change	43.87%	-9.92%	-9.92%
Cash & Equivalents	$5.047M	$6.806M	$6.810M
Short-Term Investments
Other Short-Term Assets	$3.840M	$0.00	$400.0K
YoY Change	550.85%	-100.0%	-20.0%
Inventory
Prepaid Expenses	$3.845M	$403.1K
Receivables
Other Receivables	$429.7K	$31.04K
Total Short-Term Assets	$9.322M	$7.240M	$7.240M
YoY Change	118.81%	-13.28%	-13.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$51.58K	$9.396K	$10.00K
YoY Change	525.62%
Goodwill		$0.00
YoY Change		-100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$840.6K	$578.0K	$580.0K
YoY Change	11.88%	-20.08%	-19.44%
Total Long-Term Assets	$892.2K	$587.4K	$590.0K
YoY Change	17.45%	-90.06%	-90.02%
TOTAL ASSETS
Total Short-Term Assets	$9.322M	$7.240M	$7.240M
Total Long-Term Assets	$892.2K	$587.4K	$590.0K
Total Assets	$10.21M	$7.827M	$7.830M
YoY Change	103.47%	-45.11%	-45.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.531M	$459.7K	$460.0K
YoY Change	364.09%	49.15%	-52.58%
Accrued Expenses	$1.691M	$631.4K	$630.0K
YoY Change	144.72%	-4.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.716M	$1.091M	$1.090M
YoY Change	363.93%	12.87%	12.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$284.2K	$9.711K	$10.00K
YoY Change	27.42%
Total Long-Term Liabilities	$284.2K	$9.711K	$10.00K
YoY Change	27.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.716M	$1.091M	$1.090M
Total Long-Term Liabilities	$284.2K	$9.711K	$10.00K
Total Liabilities	$7.000M	$1.101M	$1.100M
YoY Change	464.73%	13.83%	13.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$48.30M	-$28.97M
YoY Change	50.84%	136.86%
Common Stock	$51.62M	$35.79M
YoY Change	43.81%	40.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.214M	$6.727M	$6.730M
YoY Change
Total Liabilities & Shareholders Equity	$10.21M	$7.827M	$7.830M
YoY Change	103.47%	-45.11%	-45.09%

Cashflow Statement

Concept	2020 Q1	2018 Q4	2018
OPERATING ACTIVITIES
Net Income	-$4.252M	-$2.920M	-$16.74M
YoY Change	39.33%	-68.02%	45.52%
Depreciation, Depletion And Amortization	$11.95K	$0.00	$2.440K
YoY Change	939.04%
Cash From Operating Activities	-$6.598M	-$2.710M	-$10.27M
YoY Change	99.41%	182.29%	304.25%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$11.84K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	-$510.0K
YoY Change			-105.14%
Cash From Investing Activities		$0.00	-$518.8K
YoY Change			-105.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.888M	0.000	$10.11M
YoY Change			6423.84%
NET CHANGE
Cash From Operating Activities	-$6.598M	-2.710M	-$10.27M
Cash From Investing Activities		0.000	-$518.8K
Cash From Financing Activities	$6.888M	0.000	$10.11M
Net Change In Cash	$267.2K	-2.710M	-$754.0K
YoY Change	-108.1%	182.29%	-110.01%
FREE CASH FLOW
Cash From Operating Activities	-$6.598M	-$2.710M	-$10.27M
Capital Expenditures		$0.00	$11.84K
Free Cash Flow		-$2.710M	-$10.28M
YoY Change			304.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46120000	USD
CY2018Q4	dare	Accrued Indemnification Provisions AccruedIndemnificationProvisions	0	USD
CY2019Q4	dare	Accrued Indemnification Provisions AccruedIndemnificationProvisions	0	USD
CY2018Q4	dare	Accrued License Expense AccruedLicenseExpense	0	USD
CY2019Q4	dare	Accrued License Expense AccruedLicenseExpense	280833	USD
CY2017Q3	dare	Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	9900000	USD
CY2017Q3	dare	Business Combination Reverse Merger Unamortized Fair Value Of Stock Options BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions	3700000	USD
CY2018Q1	dare	Class Of Warrant Or Right Conversion Of Common Stock ClassOfWarrantOrRightConversionOfCommonStock	0.70
CY2018Q4	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	0	USD
CY2019Q4	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	2019674	USD
CY2018Q4	dare	Deferred Tax Assets Capitalized Research And Development Cost DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost	13334000	USD
CY2019Q4	dare	Deferred Tax Assets Capitalized Research And Development Cost DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost	11123000	USD
CY2018	dare	Effective Income Tax Rate Reconciliation Goodwill Impairment EffectiveIncomeTaxRateReconciliationGoodwillImpairment	-0.0648
CY2019	dare	Effective Income Tax Rate Reconciliation Goodwill Impairment EffectiveIncomeTaxRateReconciliationGoodwillImpairment	0.0000
CY2018	dare	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0031
CY2019	dare	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0002
CY2018Q4	dare	Grant Funding Recognized During Period GrantFundingRecognizedDuringPeriod	225000	USD
CY2019Q4	dare	Grant Funding Recognized During Period GrantFundingRecognizedDuringPeriod	1200000	USD
CY2018	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	0	USD
CY2019	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	238109	USD
CY2018	dare	License Fee LicenseFee	625000	USD
CY2019	dare	License Fee LicenseFee	533334	USD
CY2018	dare	Non Cash Lease Expense NonCashLeaseExpense	9319	USD
CY2019	dare	Non Cash Lease Expense NonCashLeaseExpense	-29121	USD
CY2018	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2019	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2019Q4	dare	Operating Lease Right Of Use Asset Noncurrent OperatingLeaseRightOfUseAssetNoncurrent	488280	USD
CY2018	dare	Payments For Asset Acquisition PaymentsForAssetAcquisition	507000	USD
CY2019	dare	Payments For Asset Acquisition PaymentsForAssetAcquisition	0	USD
CY2019	dare	Periodof Insufficient Cashand Liquidity Requirements PeriodofInsufficientCashandLiquidityRequirements	P12M
CY2018Q4	dare	Prepaid Clinical Expense PrepaidClinicalExpense	14547	USD
CY2019Q4	dare	Prepaid Clinical Expense PrepaidClinicalExpense	305135	USD
CY2018Q4	dare	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	562266	USD
CY2019Q4	dare	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	404141	USD
CY2018Q4	dare	Prepaid Professional Expense PrepaidProfessionalExpense	67004	USD
CY2019Q4	dare	Prepaid Professional Expense PrepaidProfessionalExpense	386328	USD
CY2018	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	10111952	USD
CY2019	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	5151702	USD
CY2018	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.00
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001401914
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24690404	shares
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-27083	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	621618	USD
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q2	dei	Entity Public Float EntityPublicFloat	12232000	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	Dare Bioscience, Inc.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2018Q4	us-gaap	Assets Assets	7827387	USD
CY2019Q4	us-gaap	Assets Assets	7442788	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	7240023	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	6443932	USD
CY2019	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	2999990	shares
CY2018	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	0	USD
CY2019	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	2369992	USD
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6805889	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4780107	USD
CY2019	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	2369992	USD
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	631351	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1000000	USD
CY2018	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2098653	USD
CY2019	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	6143893	USD
CY2019	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.00
CY2019Q4	dare	Unremitted Earnings UnremittedEarnings	0	USD
	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y6M26D
CY2019Q4	dare	Working Capital Increase Deficit WorkingCapitalIncreaseDeficit	800000	USD
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	459705	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1083183	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	139348	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	462239	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	631351	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2098653	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	32457	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	39500000	USD
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	412584	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-96728	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	135000000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3321000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	271000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-102625	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35791972	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	44564674	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	139348	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	462239	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7559846	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6805889	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4780107	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-753957	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2025782	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3750833	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6274902	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11422161	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19683401	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11422161	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19683401	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1143	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1968	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16817463	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15059321	USD
CY2019Q3	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	1100000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	59043000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63170000	USD
CY2019	us-gaap	Depreciation Depreciation	11137	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.57
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-78648	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40436000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5897	USD
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0002
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2018Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	15702	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3669000	USD
CY2019Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	42904	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M21D
CY2018	us-gaap	Depreciation Depreciation	2440	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1843
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2894
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	151486	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	608650	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1941000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1987000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59043000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59000000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63200000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63170000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	53000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	96000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0044
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0242
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0701
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.0000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0009
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0124
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0146
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	416234	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	715201	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4655837	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5265438	USD
CY2018Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5200000	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5187519	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-16707000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-13800000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-107000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-464000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16814000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14264000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3200	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	182660	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	690035	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	42000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	363000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7442788	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1091056	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	66000	USD
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2019Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	35903	USD
CY2018Q4	us-gaap	Liabilities Liabilities	1100767	USD
CY2019Q4	us-gaap	Liabilities Liabilities	7001962	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7827387	USD
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-193495	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-145223	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-237937	USD
CY2018	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-253169	USD
CY2019	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	201423	USD
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	91526	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	322482	USD
CY2019Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.07
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	866000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	461000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5612406	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10111952	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5151702	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-518836	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6143893	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10268425	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13315480	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13300000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-16738815	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-14263830	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16738815	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15053424	USD
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2018	us-gaap	Operating Expenses OperatingExpenses	16882312	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	14344880	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-16882312	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-14344880	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	223000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	800000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	410896	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	411000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	154000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.75
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	577968	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	935325	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-78648	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5897	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9711	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	389556	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	143497	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	81050	USD
CY2018Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	31037	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	555210	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11836	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	403097	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1108615	USD
CY2018Q4	us-gaap	Prepaid Insurance PrepaidInsurance	321546	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	417152	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9396	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63531	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6413956	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8546108	USD
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	507000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	-202096	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28969767	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44000000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44023191	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	583697	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	139348	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	462239	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.21
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.20
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0252
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0244
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	578445	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.03
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	924000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	935000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	72000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	846000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000.0	shares
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	734235	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	13292783	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	6726620	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	440826	USD
CY2017Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2019	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10
CY2018	us-gaap	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit	23600000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	78000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	83000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	55600000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4100000	USD
CY2018	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	800000	USD
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	789594	USD
CY2019Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.98
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10732421	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15578959	shares
CY2019	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Indemnifications</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As permitted under Delaware law, the Company has entered into indemnification agreements with its officers and directors that provide that the Company will indemnify the directors and officers for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by such director or officer in any action or proceeding arising out of their service as a director and/or officer. The term of the indemnification is for the officer’s or director’s lifetime. During the year ended </font><font style="font-family:Arial;font-size:10pt;">December 31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company did not experience any losses related to those indemnification obligations. The Company does not expect significant claims related to these indemnification obligations, and consequently, has concluded the fair value of the obligations is not material. Accordingly, as of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2019</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> amounts have been accrued related to such indemnification provisions.</font></div></div>
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company maintains cash balances at various financial institutions and such balances commonly exceed the </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;"> amount insured by the Federal Deposit Insurance Corporation. The Company also maintains money market funds at various financial institutions which are not federally insured although are invested primarily in the U.S. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant risk with respect to such cash and cash equivalents.</font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of stock-based compensation, goodwill impairment and purchase accounting. Actual results could differ from those estimates and could materially affect the reported amounts of assets, liabilities and future operating results.</font></div></div>

Files In Submission

Name	View Source	Status
0001401914-20-000042-index-headers.html	Edgar Link	pending
0001401914-20-000042-index.html	Edgar Link	pending
0001401914-20-000042.txt	Edgar Link	pending
0001401914-20-000042-xbrl.zip	Edgar Link	pending
dare-20191231.xml	Edgar Link	completed
dare-20191231.xsd	Edgar Link	pending
dare-20191231x10k.htm	Edgar Link	pending
dare-20191231xex211.htm	Edgar Link	pending
dare-20191231xex231.htm	Edgar Link	pending
dare-20191231xex311.htm	Edgar Link	pending
dare-20191231xex312.htm	Edgar Link	pending
dare-20191231xex321.htm	Edgar Link	pending
dare-20191231xex322.htm	Edgar Link	pending
dare-20191231_cal.xml	Edgar Link	unprocessable
dare-20191231_def.xml	Edgar Link	unprocessable
dare-20191231_lab.xml	Edgar Link	unprocessable
dare-20191231_pre.xml	Edgar Link	unprocessable
darebioinlinefullcolorrgba04.jpg	Edgar Link	pending
exhibit1010c.htm	Edgar Link	pending
exhibit1010c001.jpg	Edgar Link	pending
exhibit1010c002.jpg	Edgar Link	pending
exhibit1010d.htm	Edgar Link	pending
exhibit1010d001.jpg	Edgar Link	pending
exhibit1010d002.jpg	Edgar Link	pending
exhibit1010d003.jpg	Edgar Link	pending
exhibit1016.htm	Edgar Link	pending
exhibit1016001.jpg	Edgar Link	pending
exhibit1016002.jpg	Edgar Link	pending
exhibit1016003.jpg	Edgar Link	pending
exhibit1016004.jpg	Edgar Link	pending
exhibit1016005.jpg	Edgar Link	pending
exhibit1016006.jpg	Edgar Link	pending
exhibit1016007.jpg	Edgar Link	pending
exhibit1016008.jpg	Edgar Link	pending
exhibit1016009.jpg	Edgar Link	pending
exhibit1016010.jpg	Edgar Link	pending
exhibit1016011.jpg	Edgar Link	pending
exhibit1016012.jpg	Edgar Link	pending
exhibit1016013.jpg	Edgar Link	pending
exhibit1016014.jpg	Edgar Link	pending
exhibit1016015.jpg	Edgar Link	pending
exhibit1016016.jpg	Edgar Link	pending
exhibit1016017.jpg	Edgar Link	pending
exhibit1016018.jpg	Edgar Link	pending
exhibit1016019.jpg	Edgar Link	pending
exhibit1016020.jpg	Edgar Link	pending
exhibit1016021.jpg	Edgar Link	pending
exhibit1016022.jpg	Edgar Link	pending
exhibit1016023.jpg	Edgar Link	pending
exhibit1016024.jpg	Edgar Link	pending
exhibit1016025.jpg	Edgar Link	pending
exhibit1016026.jpg	Edgar Link	pending
exhibit1016027.jpg	Edgar Link	pending
exhibit1016028.jpg	Edgar Link	pending
exhibit1016029.jpg	Edgar Link	pending
exhibit1016030.jpg	Edgar Link	pending
exhibit1016031.jpg	Edgar Link	pending
exhibit1016032.jpg	Edgar Link	pending
exhibit1016033.jpg	Edgar Link	pending
exhibit1016034.jpg	Edgar Link	pending
exhibit1016035.jpg	Edgar Link	pending
exhibit1016036.jpg	Edgar Link	pending
exhibit1016037.jpg	Edgar Link	pending
exhibit46.htm	Edgar Link	pending
exhibit46001.jpg	Edgar Link	pending
exhibit46002.jpg	Edgar Link	pending
exhibit46003.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2020 Q1 Form 10-K Financial Statement

#000140191420000042 Filed on March 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2020 Q1 Form 10-K Financial Statement

#000140191420000042 Filed on March 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare